Stock code: 688202 Stock abbreviation: Medicilon Announcement No.: 2024-043

Shanghai Medicililon Biopharmaceutical Co., Ltd

About participating in the 2024 semi-annual Science and Technology Innovation Board Pharmaceutical and Biological Products Special Session

Announcement of the collective performance briefing

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

Online communication time: 14:00-16:00 p.m. on September 18, 2024 (Wednesday).

The meeting was held in a way that was interactive with text on the Internet

Interactive Platform: Shanghai Stock Exchange Roadshow Center (https://roadshow.sseinfo.com/)

Investors can do so by 16:00 on September 13, 2024 (Friday) via the company's phone or investor close

The mailbox (IR@medicilon.com.cn) will provide the company with the issues that need to be understood and concerned in advance. The company will answer the questions of general concern to investors in the text interactive session.

Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has been approved in August 2024

The company's 2024 semi-annual report and its summary were disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the 20th. In order to facilitate investors to have a more comprehensive and in-depth understanding of the company's 2024 semi-annual operating results, financial status and development philosophy, the company participated in the 2024 semi-annual pharmaceutical and biological products special collective performance briefing hosted by the Shanghai Stock Exchange. The event will be held in the form of online text interaction

Yes, investors can register at the SSE Roadshow Centre at that time

(https://roadshow.sseinfo.com/) Participate in online interactive exchanges.

1. Type of briefing

The company will interact and communicate with investors on the specific situation of operating results and financial indicators for the first half of 2024, and answer questions of general concern to investors within the scope of information disclosure.

2. The time, place and method of the briefing meeting

(1) Online communication time: 14:00-16:00 p.m. on September 18, 2024 (Wednesday).

(2) The method of convening the meeting: online text interaction

(3) Online text interaction platform: SSE Roadshow Center (https://roadshow.sseinfo.com/)

3. Participants

FOUNDER AND CEO: CHUN-LIN CHEN

Director, Deputy General Manager and Chief Commercial Officer: Cai Jinna

Independent directors: Ma Dawei, Lai Weidong, Xu Jinye

Chief Financial Officer and Vice President of Operations: Liu Binbin

Chief Scientific Officer: Peng Shuangqing

Secretary of the Board of Directors: Xue Chao

(In case of special circumstances, participants may be adjusted.) ）

Fourth, the way for investors to participate

(1) Investors can connect from 14:00 to 16:00 on September 18, 2024 (Wednesday).

Log in to the SSE Roadshow Center (https://roadshow.sseinfo.com/) online to participate in this performance briefing, and the company will answer investors' questions in a timely manner.

(2) Investors can call or invest through the company before 16:00 on September 13, 2024 (Friday).

The Investor Relations Mailbox (IR@medicilon.com.cn) provides the company with the issues that need to be understood and concerned in advance. The company will answer the questions of general concern to investors in the text interactive session.

5. Contact person and consultation method

Contact Department: Securities Office

Tel: 021-58591500*8818

Email: IR@medicilon.com.cn

6. Other matters

After the investor briefing is held, investors can check the convening and main content of the investor briefing through the Shanghai Stock Exchange Roadshow Center (https://roadshow.sseinfo.com/).

The announcement is hereby made.

Board of Directors of Shanghai Medicilon Biopharmaceutical Co., Ltd

September 7, 2024